8-KItem 2.02 · Results of OperationsItem 8.01 · Other EventsItem 9.01 · Financial Statements
Revvity reports Q2 growth, raises guidance and plans China IDX divestiture
Filed with the SEC on · Summarized by InvestorsBot
Revvity reported second-quarter 2026 revenue of $730 million and adjusted EPS of $1.41 for the period ended July 5, 2026; pro forma revenue was $711 million, up 4%, with pro forma organic growth of 3%. On July 31, 2026, Revvity entered an agreement to sell substantially all China Immunodiagnostics assets for up to $200 million, subject to adjustments and approvals, with closing expected by the end of 2027; the business represented about 6% of 2025 revenue. Revvity raised its 2026 pro forma guidance to $2.83 billion-$2.86 billion in revenue, 4%-5% organic growth and adjusted EPS of $5.30-$5.40.